Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39770248238389dd869fdaef87983879 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F16-285 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06N20-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06N3-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-60 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-12 |
filingDate |
2018-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46018b5b4d258358baf325394c93990b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6a8fdf5d4ead170d215073da873b92c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5bfc25b37dd0a2a2aa5e578c0c10a33 |
publicationDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2018232320-A2 |
titleOfInvention |
Prognostic indicators of poor outcomes in praegnant metastatic breast cancer cohort |
abstract |
Transcriptomics data from tumor tissue of patients diagnosed with metastatic breast cancer are clustered and associated with overall survival of the patients. A subset of genes from one of the cluster associated with poor outcome are used to generate a survival prediction model predicting a survival time based on expression levels of a plurality of genes. Using such generated survival prediction model, a survival time of a patient diagnosed with metastatic breast cancer can be predicted and a treatment regimen can be updated or generated based on the survival time. |
priorityDate |
2017-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |